poisar

Stocks · News reference

Barclays Maintains Equal-Weight on Ingredion, Lowers Price Target to $118

BenzingaAug 5, 2026, 12:50 PMBenzinga Newsdesk

Barclays analyst Benjamin Theurer maintains Ingredion (NYSE:INGR) with a Equal-Weight and lowers the price target from $120 to $118.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 5, 2026, 12:50 PM
Checked
Aug 5, 2026, 12:50 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 6, 2026, 2:47 PMNa

    Ingredion Incorporated 公佈 2026 年第二季度業績

    Ingredion Incorporated reported Q2 2026 results with reported diluted EPS of $1.78 and adjusted EPS of $2.82, down from $2.99 and $2.87 respectively in Q2 2025. Net sales increased 1% to $1.85 billion, while adjusted operating income declined 5%. The company completed the sale of its Pakistan business majority stake and announced that Tate & Lyle shareholders approved its 595 pence all-cash acquisition offer. Ingredion reaffirmed full-year 2026 guidance with reported EPS of $9.15-$9.75 and adjusted EPS of $10.30-$10.90.

    Read original at globenewswire-inc
  2. Globenewswire IncAug 6, 2026, 2:47 PMNa

    Ingredion Incorporated 公布 2026 年第二季度业绩

    Ingredion Incorporated reported Q2 2026 results with reported diluted EPS of $1.78 versus $2.99 in Q2 2025, representing a 40% decline. The company reaffirmed full-year 2026 guidance with adjusted EPS expected between $10.30-$10.90. Notably, Tate & Lyle shareholders approved Ingredion's £595 pence per share all-cash acquisition offer on July 28, 2026, marking a significant step toward completing the transaction.

    Read original at globenewswire-inc
  3. Globenewswire IncAug 6, 2026, 2:47 PMNa

    Ingredion, 2026년 2분기 견조한 실적 발표

    Ingredion Incorporated reported Q2 2026 results showing a 31% decline in reported operating income and 5% decline in adjusted operating income year-over-year, with diluted EPS of $1.78 (reported) and $2.82 (adjusted). The company successfully sold a majority stake in its Pakistan business and received shareholder approval from Tate & Lyle for its 595 pence all-cash acquisition offer. Despite operational challenges at the Argo plant, the Texture & Healthful Solutions segment showed nine consecutive quarters of net volume growth. Full-year 2026 guidance was maintained with expected reported EPS of $9.15-$9.75 and adjusted EPS of $10.30-$10.90.

    Read original at globenewswire-inc